Menu
Search
|

Menu

Close
X

Unum Therapeutics Inc UMRX.OQ (NASDAQ Stock Exchange Global Select Market)

1.97 USD
-0.05 (-2.48%)
As of Sep 13
Previous Close 2.02
Open 2.05
Volume 7,646
3m Avg Volume 52,345
Today’s High 2.11
Today’s Low 1.96
52 Week High 12.98
52 Week Low 1.54
Shares Outstanding (mil) 30.12
Market Capitalization (mil) 60.24
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
3
FY18
10
FY17
8
FY16
3
EPS (USD)
FY19
-0.389
FY18
-1.597
FY17
-1.168
FY16
-0.356
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
5.70
7.90
Price to Book (MRQ)
vs sector
1.22
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-104.76
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Bruce Booth
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Charles Wilson
President, Chief Executive Officer, Director, Since 2019
Salary: $486,000.00
Bonus: $248,160.00
Matthew Osborne
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Geoffrey Hodge
Chief Technology Officer, Since 2015
Salary: --
Bonus: --
John Green
Principal Accounting Officer, Controller, Senior Director of Finance, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Cambridgepark Dr Ste 3100
CAMBRIDGE   MA   02140-2307

Phone: +1617.9455576

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

SPONSORED STORIES